Bariatric treatments for adult obesity - Institute of Health Economics

Table T.D.2: Characteristics of the primary studies assessed in SRs/HTAs (cont’d)Behavioural therapy (BT)Shaw et al.,2005 1536 RCTsPharmacotherapyN = 3495Mean age (yr): weighted mean 43.1 in 18 trials that reported mean age; rangefrom 16–75 in the remaining 18 trials that reported only age range% females: 100% men (2 trials), 100% women (14 trials), 25% men and 75%women (across 20 trials)Ethnic origin: 29 trials conducted in US, one each in Canada, Columbia,Netherlands, Spain, Sweden, Switzerland, the United KingdomBaseline weight (kg): NAMean baseline BMI (kg/m 2 ): > 25 in most studiesComorbidity: diabetes (two trials), impaired glucose tolerance (two trials), mildhypertension (one trial), binge eating disorder (two trials)Type: BT, BT+D/E, CBT, cognitive therapy, hypnotherapy, relaxationDuration: median 12 weeks (range from 4 weeks to 12 months)Intensity: range from daily to monthlyDrop-out rate: ≤ 15% in all studiesLength of follow-up: range 3 to 36 monthsJohansson etal., 2009 5928 RCTsPadwal et al.,2004 2030 RCTs(16 on orlistat,10 onsibutramine, 4on rimonabant)N = 13,457 (orlistat n=7038, sibutramine n=1475, rimonabant n=4944)Mean age (yr): range from 41–59% female: greater proportion of women than of men in most studiesEthnic origin: predominantly whiteBaseline weight (kg): NAMean baseline BMI (kg/m 2 ): range from 33–38Comorbidity: hypertension, hypercholesterolemia, T2DM, dyslipidemia, coronaryartery disease, risk factors of CVDType: orlistat, sibutramine, rimonabantDosage: orlistat 360 mg/day, sibutramine (10–15 mg/day), rimonabant (20mg/day)Co-intervention: diet with or without exercise in all studiesDrop-out rate: 30% for orlistat, 34% for sibutramine, 39% for rimonabantLength of follow-up: 12 to 18 monthsOrlistat Sibutramine Rimonabant Type Orlistat Sibutramine RimonabantN = 19,889 10,631 2623 6635 Dosage 120 mg t.i.d. 10–20 mg/day;15 mg/day mostcommonly usedMean age (yr) 47 45 48 Co-% females 66% 73% 73%interventionEthnic origin 89% Caucasian 95% Caucasian 87% CaucasianMean baselineweight (kg)Mean baselineBMI (kg/m 2 )Comorbidity104 97 10236.3 35.1 36.5dyslipidemia, DM,HTN, impairedglucose toleranceHTN, DMdyslipidemia, DM,HTNDrop-out rate(range)Length offollow-up(yrs)standardized, lowfat, hypocaloricdiet;encouragementto exercisedietarymodification withor without adviceto exercise20 mg/daydietarymodificationwith or withoutadvice toexercise30% (0–66%) 40% (11%–51%) 40% (32–49%)1–4 1–1.5 1–2Bariatric treatments for adult obesity 130